Retia Medical, a Valhalla, NY-based innovator in advanced hemodynamic monitoring, secured $15m in Series B funding.
The round was led by Fresenius Medical Care Ventures with participation from a second strategic investor, Red Cedar Ventures, and existing investor, the Pritzker-Vlock Family Office.
The company will use the funding to expand its commercial team and accelerate the development of its next-generation algorithms for guiding care for high-risk patients.
Led by Marc Zemel, S.M., M.B.A., Co-Founder and Chief Executive Officer, Retia Medical aims to provide accurate cardiovascular information and insights to help clinicians improve outcomes for high-risk patients. The company brings together expertise in physiology, signal processing, data science, and computational algorithms to engineer innovative hemodynamic monitoring solutions that give clinicians accurate, real-time data that they can rely on to make patient care decisions.
RELATED: Oxford Science Enterprises Raises £250 Million
Its Argos Cardiac Output Monitor enables individualized, data-driven care to improve outcomes and lower costs for high-risk surgical and critically ill patients. This hemodynamic monitor features the Multi-Beat Analysis (MBATM) algorithm for accurate cardiac output measurements. The proprietary MBA algorithm analyzes multiple heartbeats to model the patient’s physiology and therefore provide high-quality hemodynamic data in real-time. The system detects important changes in a patient’s status and enables immediate clinical intervention, when required. Designed to streamline care, the next-generation Argos Monitor can be set up in less than one minute and leverages a patient’s existing arterial line for immediate use without requiring costly additional disposables or connections.
